In the BioHarmony Drug Report Database
Inebilizumab-cdon
Uplizna (inebilizumab) is an antibody pharmaceutical. Inebilizumab was first approved as Uplizna on 2020-06-11. It is used to treat neuromyelitis optica in the USA. The pharmaceutical is active against B-lymphocyte antigen CD19.
Trade Name
|
Uplizna |
|---|---|
Common Name
|
inebilizumab |
ChEMBL ID
|
CHEMBL2109334 |
Indication
|
neuromyelitis optica |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
